Key Metrics of Sarepta Therapeutics
Revenue$1.2B▲ 33.3% YoYFY 2023
Operating income−$268M▲ 50.1% YoY
Net profit−$536M▲ 23.8% YoY
Shareholders' equity$859M
Market cap$2.0BSRPT · $18.62
Competitors10identified
About Sarepta Therapeutics
Sectors
Company details
- Website
- sarepta.com
- Listed
- Nasdaq: SRPT
Operational Areas of Sarepta Therapeutics
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Company summary
Legal nameSarepta Therapeutics Inc.
TickerSRPT
ExchangeNasdaq
CountryUnited States
SEC CIK0000873303
Listed since—
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
Websitehttp://www.sarepta.com
US market & SEC filings
SRPT · Nasdaq · SEC CIK 0000873303
Last price · 02 Nov 2026
$18.62
−3.17%
Market cap$2.0B
P/E—On FY 2023 diluted EPS
Volume1,318,230
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited States
SRPT share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeCambridge
GSTIN—
Email—
Websitehttp://www.sarepta.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Sarepta Therapeutics
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lilly.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | jjmt.com.tw | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pg.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | merck.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | amgen.com | 1983 | United States | |
| Part of Gilead Sciences. | gilead.com | 1992 | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | abbott.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pfizer.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | marriott.com.cn | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | hcahealthcare.com | 2011 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
pharmaceutical industry
Filings
No filings on record yet.